Introduction: Determining the dignity of intraductal papillary mucinous neoplasms (IPMNs) by imaging procedures is challenging. Various CT-based criteria were evaluated. Patients and Methods: Preoperative CT scans from 47 patients with IPMN were analyzed. Predefined criteria of malignancy were compared between patients with benign (bIPMN; n = 28) and malignant (mIPMN; n = 19) tumors, and a summation score was determined. Results: Preoperative carbohydrate-antigen 19-9 levels were higher in patients with mIPMN (p = 0.013). The diameter of the main pancreatic duct was greater in patients with mIPMN (p < 0.0001). More patients with mIPMN showed bile duct obstruction (p = 0.0076), solid tumor components (p = 0.0076), contrast enhancement in cystic walls (p = 0.0086), peripancreatic lymph nodes (p = 0.0076), and abrupt diameter changes of the main pancreatic duct (p = 0.0008). The CT density of the cysts was higher in mIPMN (p = 0.0063). The diagnostic accuracy of the summation score (sensitivity: 0.84, specificity: 0.96) was greater when compared to each individual CT parameter. Conclusions: The prevalence and extent of various CT-based abnormalities are greater in patients with mIPMN, but the wide overlap limits the diagnostic value of each individual parameter. A simple summation score largely enhances the diagnostic accuracy.

Journal Section:
Original Paper
Keywords:
Sensitivity, Intraductal papillary mucinous neoplasm, Computed tomography, Specificity, Malignancy
1.
Cooper CL, O'Toole SA, Kench JG: Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology 2013;45:286-304.
2.
Belyaev O, Seelig MH, Muller CA, Tannapfel A, Schmidt WE, Uhl W: Intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2008;42:284-294.
3.
Spinelli KS, Fromwiller TE, Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, et al: Cystic pancreatic neoplasms: observe or operate. Ann Surg 2004;239:651-657; discussion 657-659.
4.
de Jong K, Nio CY, Hermans JJ, Dijkgraaf MG, Gouma DJ, van Eijck CH, et al: High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol 2010;8:806-811.
5.
Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788-797; discussion 797-799.
6.
Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-197.
7.
Uhl W, Belyaev O, Herzog T, Mueller CA, Seelig M, Schmidt W, et al: [Intraductal papillary mucinous neoplasms of the pancreas: pro surgical therapy - pro surveillance]. Z Gastroenterol 2008;46:1290-1297.
8.
Khalid A, Brugge W: ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007;102:2339-2349.
9.
Mayerle J, Kraft M, Menges P, Simon P, Ringel J, Partecke LI, et al: [Intraductal papillary mucinous neoplasia: which findings support observation?]. Chirurg 2012;83:123-129.
10.
Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244-1249.
11.
Fujino Y, Matsumoto I, Ueda T, Toyama H, Kuroda Y: Proposed new score predicting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Am J Surg 2007;194:304-307.
12.
Shin SH, Han DJ, Park KT, Kim YH, Park JB, Kim SC: Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg 2010;34:776-783.
13.
Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH: Histological typing of tumours of the exocrine pancreas; in WHO International Histological Classification of Tumours, ed 2. New York, Springer Verlag, Berlin Heidelberg, 1996, pp 12-19.
14.
Brambs HJ, Juchems M: Radiologische Diagnostik der intraduktalen papillär muzinösen Neoplasie. Chirurg 2012;83:116-122.
15.
Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S: Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology 2008;248:876-886.
16.
Kato Y, Takahashi S, Gotohda N, Konishi M: Risk factors for malignancy in branched-type intraductal papillary mucinous neoplasms of the pancreas during the follow-up period. World J Surg 2015;39:244-250.
17.
Mimura T, Masuda A, Matsumoto I, Shiomi H, Yoshida S, Sugimoto M, et al: Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 2010;44:e224-e229.
18.
Hirano S, Kondo S, Tanaka E, Shichinohe T, Suzuki O, Shimizu M, et al: Role of CT in detecting malignancy during follow-up of patients with branch-type IPMN of the pancreas. Hepatogastroenterology 2009;56:515-518.
19.
Gupta R, Mortele KJ, Tatli S, Girshman J, Glickman JN, Levy AD, et al: Pancreatic intraductal papillary mucinous neoplasms: role of CT in predicting pathologic subtypes. AJR Am J Roentgenol 2008;191:1458-1464.
20.
Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S: Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology 2008;248:876-886.
21.
Schrader H, Wiese M, Ellrichmann M, Belyaev O, Uhl W, Tannapfel A, et al: Diagnostic value of quantitative EUS elastography for malignant pancreatic tumors: relationship with pancreatic fibrosis. Ultraschall Med 2012;33:E196-E201.
22.
Rafique A, Freeman S, Carroll N: A clinical algorithm for the assessment of pancreatic lesions: utilization of 16- and 64-section multidetector CT and endoscopic ultrasound. Clin Radiol 2007;62:1142-1153.
23.
Tirkes T, Menias CO, Sandrasegaran K: MR imaging techniques for pancreas. Radiol Clin North Am 2012;50:379-393.
24.
Gardner TB, Gordon SR: Interobserver agreement for pancreatic endoscopic ultrasonography determined by same day back-to-back examinations. J Clin Gastroenterol 2011;45:542-545.
25.
Choi JY, Lee JM, Lee MW, Kim SJ, Choi SY, Kim JY, et al: Magnetic resonance pancreatography: comparison of two- and three-dimensional sequences for assessment of intraductal papillary mucinous neoplasm of the pancreas. Eur Radiol 2009;19:2163-2170.
26.
Vege SS, Ziring B, Jain R, Moayyedi P; Clinical Guidelines Committee; American Gastroenterology Association: American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015;148:819-822; quiz e12-e13.
27.
Scheiman JM, Hwang JH, Moayyedi P: American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015;148:824-848.e22.
28.
Lawson RD, Hunt GC, Giap AQ, Krinsky ML, Slezak J, Tang RS, et al: Pancreatic cysts suspected to be branch duct intraductal papillary mucinous neoplasm without concerning features have low risk for development of pancreatic cancer. Ann Gastroenterol 2015;28:487-494.
29.
Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Shimizu A, et al: The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2012;255:517-522.
30.
Fritz S, Hackert T, Hinz U, Hartwig W, Buchler MW, Werner J: Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 2011;98:104-110.
31.
Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M: Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 2010;251:70-75.
32.
Menge BA, Schrader H, Breuer TG, Dabrowski Y, Uhl W, Schmidt WE, et al: Metabolic consequences of a 50% partial pancreatectomy in humans. Diabetologia 2009;52:306-317.
33.
Pannala R, Basu A, Petersen GM, Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
34.
Schrader H, Menge BA, Belyaev O, Uhl W, Schmidt WE, Meier JJ: Amino acid malnutrition in patients with chronic pancreatitis and pancreatic carcinoma. Pancreas 2009;38:416-421.
35.
Hart PA, Chari ST: Diabetes mellitus and pancreatic cancer: why the association matters? Pancreas 2013;42:1207-1209.
36.
Chari ST, Zapiach M, Yadav D, Rizza RA: Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 2005;5:229-233.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.